ArticleMedical microbiology and immunology2004
Miltefosine (Impavido): the first oral treatment against leishmaniasis.
Article in Medical microbiology and immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic Review of Host-Mediated Activity of Miltefosine in Leishmaniasis through Immunomodulation.Antimicrobial agents and chemotherapy · 2019Pooled it
- A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis.Frontiers in cellular and infection microbiology · 2021Trial
- Potential efficacy of repurposed drugs for treating drug-resistant visceral leishmaniasis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Identification of Potential Therapeutic Agents for Primary Amebic Meningoencephalitis Using Text Mining and Bioinformatics Analyses.Analytical cellular pathology (Amsterdam) · 2026Article
- Computational Investigation of the Potential Antileishmanial Mechanism of the Nitroindazole Derivative VATR131.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Treatment of Cutaneous Leishmaniasis and Insights into Species-Specific Responses: A Narrative Review.Infectious diseases and therapy · 2022Review
- Total synthesis of (+)-spiroindimicin A and congeners unveils their antiparasitic activity.Chemical science · 2021Article
- Computational approaches for drug discovery against trypanosomatid-caused diseases.Parasitology · 2020Review
- Applications of Nanomaterials in Leishmaniasis: A Focus on Recent Advances and Challenges.Nanomaterials (Basel, Switzerland) · 2019Review
- Simple and efficient synthesis of 5'-aryl-5'-deoxyguanosine analogs by azide-alkyne click reaction and their antileishmanial activities.Molecular diversity · 2016Article
- Advances in Development of New Treatment for Leishmaniasis.BioMed research international · 2015Review
- Crovirin, a snake venom cysteine-rich secretory protein (CRISP) with promising activity against Trypanosomes and Leishmania.PLoS neglected tropical diseases · 2014Article
- Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms.Parasitology research · 2012Article
- Antiproliferative, Ultrastructural, and Physiological Effects of Amiodarone on Promastigote and Amastigote Forms of Leishmania amazonensis.Molecular biology international · 2011Article
- Phospholipid and sphingolipid metabolism in Leishmania.Molecular and biochemical parasitology · 2010Review
- Miltefosine efficiently eliminates Leishmania major amastigotes from infected murine dendritic cells without altering their immune functions.Antimicrobial agents and chemotherapy · 2010Article
- In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects.Antimicrobial agents and chemotherapy · 2008Article
- In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.Antimicrobial agents and chemotherapy · 2007Article
- Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes.Antimicrobial agents and chemotherapy · 2007Article
- Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.Antimicrobial agents and chemotherapy · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.
Indexed as
Identifiers
14513375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.